vesicular stomatitis indiana virus

Summary

Summary: The type species of VESICULOVIRUS causing a disease symptomatically similar to FOOT-AND-MOUTH DISEASE in cattle, horses, and pigs. It may be transmitted to other species including humans, where it causes influenza-like symptoms.

Top Publications

  1. ncbi Functional role of type I and type II interferons in antiviral defense
    U Muller
    Institute of Molecular Biology I, University of Zurich, Switzerland
    Science 264:1918-21. 1994
  2. ncbi VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
    David F Stojdl
    Ottawa Regional Cancer Centre Research Laboratories, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6
    Cancer Cell 4:263-75. 2003
  3. ncbi Defective translational control facilitates vesicular stomatitis virus oncolysis
    Siddharth Balachandran
    Department of Microbiology and Immunology and Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL 33136, USA
    Cancer Cell 5:51-65. 2004
  4. pmc Interferon gamma-producing gammadelta T cell-dependent antibody isotype switching in the absence of germinal center formation during virus infection
    K J Maloy
    Institute of Experimental Immunology, Department of Pathology, University of Zurich, Schmelzbergstrasse 12, CH 8091, Zurich, Switzerland
    Proc Natl Acad Sci U S A 95:1160-5. 1998
  5. ncbi Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer
    Boris A Hadaschik
    The Prostate Centre at Vancouver General Hospital, Department of Urologic Sciences, and Brain Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
    Cancer Res 68:4506-10. 2008
  6. ncbi Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence
    Akinori Takaoka
    Department of Immunology, Faculty of Medicine and Graduate School of Medicine, University of Tokyo, Hongo 7 3 1, Bunkyo ku, Tokyo 113 0033, Japan
    Nature 424:516-23. 2003
  7. pmc Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations
    David K Clarke
    Wyeth Vaccines Discovery Research, 401 N Middletown Road, Bldg 180 267, Pearl River, NY 10965, USA
    J Virol 81:2056-64. 2007
  8. ncbi Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease
    J E Durbin
    Department of Pathology, New York University School of Medicine, New York 10016, USA
    Cell 84:443-50. 1996
  9. ncbi Requirement for cyclophilin A for the replication of vesicular stomatitis virus New Jersey serotype
    Santanu Bose
    Department of Virology, Lerner Research Institute, Room NN 10, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Gen Virol 84:1687-99. 2003
  10. ncbi Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus
    Rosa Maria Diaz
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 67:2840-8. 2007

Research Grants

  1. Mechanisms of VSV-mediated Oncolysis
    Glen N Barber; Fiscal Year: 2010
  2. Determinants of RNA virus evolution
    ISABEL NOVELLA; Fiscal Year: 2009
  3. SURVIVAL AND EXTINCTION IN RNA VIRUS POPULATIONS
    ISABEL NOVELLA; Fiscal Year: 2003
  4. Targeted Recombinant VSV Virus to Treat Breast Cancer
    Ira Bergman; Fiscal Year: 2008
  5. Budding of Negative-sense RNA Viruses
    RONALD HARTY; Fiscal Year: 2006
  6. VSV-based Therapeutic Papilloma Vaccine
    Janet Brandsma; Fiscal Year: 2007
  7. Papillomavirus E2 as a cervical/anal cancer drug target
    Janet Brandsma; Fiscal Year: 2005
  8. Immunogenicity of Hepatitis C Virus (HCV) like particles
    Glen Barber; Fiscal Year: 2007
  9. Ebola Virus VP40-Host Interactions In VIvo
    RONALD HARTY; Fiscal Year: 2005
  10. Packaging of Ebola Virus RNA into Budding VLPs
    RONALD HARTY; Fiscal Year: 2008

Detail Information

Publications211 found, 100 shown here

  1. ncbi Functional role of type I and type II interferons in antiviral defense
    U Muller
    Institute of Molecular Biology I, University of Zurich, Switzerland
    Science 264:1918-21. 1994
    ..Comparison of mice lacking either type I or type II IFN receptors showed that, at least in response to some viruses, both IFN systems are essential for antiviral defense and are functionally nonredundant...
  2. ncbi VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
    David F Stojdl
    Ottawa Regional Cancer Centre Research Laboratories, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6
    Cancer Cell 4:263-75. 2003
    ..While highly attenuated for growth in normal mice, both AV1 and AV2 effected complete and durable cures in the majority of treated animals when delivered systemically...
  3. ncbi Defective translational control facilitates vesicular stomatitis virus oncolysis
    Siddharth Balachandran
    Department of Microbiology and Immunology and Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL 33136, USA
    Cancer Cell 5:51-65. 2004
    ..Thus, defects in translational regulation can cooperate with impaired IFN signaling to facilitate VSV replication, and may represent a common hallmark of tumorigenesis...
  4. pmc Interferon gamma-producing gammadelta T cell-dependent antibody isotype switching in the absence of germinal center formation during virus infection
    K J Maloy
    Institute of Experimental Immunology, Department of Pathology, University of Zurich, Schmelzbergstrasse 12, CH 8091, Zurich, Switzerland
    Proc Natl Acad Sci U S A 95:1160-5. 1998
    ..Thus, during viral infection of alphabeta T cell-deficient mice, gammadelta T cells may provide the signals that are required for isotype switching...
  5. ncbi Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer
    Boris A Hadaschik
    The Prostate Centre at Vancouver General Hospital, Department of Urologic Sciences, and Brain Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
    Cancer Res 68:4506-10. 2008
    ..These findings provide preclinical proof-of-principle for the intravesical use of VSV against non-muscle-invasive bladder cancer, especially in IFN-refractory patients...
  6. ncbi Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence
    Akinori Takaoka
    Department of Immunology, Faculty of Medicine and Graduate School of Medicine, University of Tokyo, Hongo 7 3 1, Bunkyo ku, Tokyo 113 0033, Japan
    Nature 424:516-23. 2003
    ..Our study reveals a hitherto unrecognized link between p53 and IFN-alpha/beta in tumour suppression and antiviral immunity, which may have therapeutic implications...
  7. pmc Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations
    David K Clarke
    Wyeth Vaccines Discovery Research, 401 N Middletown Road, Bldg 180 267, Pearl River, NY 10965, USA
    J Virol 81:2056-64. 2007
    ..The results show synergistic rather than cumulative increases in attenuation and demonstrate a new approach to the attenuation of VSV and possibly other viruses...
  8. ncbi Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease
    J E Durbin
    Department of Pathology, New York University School of Medicine, New York 10016, USA
    Cell 84:443-50. 1996
    ..Thus, STAT1 appears to be specific for IFN pathways that are essential for viability in the face of otherwise innocuous pathogens...
  9. ncbi Requirement for cyclophilin A for the replication of vesicular stomatitis virus New Jersey serotype
    Santanu Bose
    Department of Virology, Lerner Research Institute, Room NN 10, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Gen Virol 84:1687-99. 2003
    ..The different requirements for CypA by two serologically different viruses belonging to the same family has highlighted the utilization of specific host factors during their evolutionary lineages...
  10. ncbi Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus
    Rosa Maria Diaz
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 67:2840-8. 2007
    ..Therefore, our results show that strategies which enhance immune activation against tumor-associated antigens can also be used to enhance the efficacy of virotherapy...
  11. ncbi Inhibition of host and viral translation during vesicular stomatitis virus infection. eIF2 is responsible for the inhibition of viral but not host translation
    John H Connor
    Department of Biochemistry, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    J Biol Chem 280:13512-9. 2005
    ....
  12. ncbi Vesicular stomatitis virus as an oncolytic vector
    Glen N Barber
    Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida 33136, USA
    Viral Immunol 17:516-27. 2004
    ..Collectively, our data and others demonstrate that VSV as well as other RNA viruses could provide a promising and exciting approach to cancer therapy...
  13. ncbi Preferential localization of effector memory cells in nonlymphoid tissue
    D Masopust
    Division of Immunology, Department of Medicine, University of Connecticut Health Center, Farmington, CT 06030, USA
    Science 291:2413-7. 2001
    ..These results point to the existence of a population of extralymphoid effector memory T cells poised for immediate response to infection...
  14. ncbi Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment
    Kathleen M Daddario-DiCaprio
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    Lancet 367:1399-404. 2006
    ..We aimed to test the efficacy of a replication-competent vaccine based on attenuated recombinant vesicular stomatitis virus (rVSV), as a postexposure treatment for MARV haemorrhagic fever...
  15. ncbi Promotion of vesicular stomatitis virus fusion by the endosome-specific phospholipid bis(monoacylglycero)phosphate (BMP)
    Shoshannah L Roth
    Department of Microbiology and Immunology, Cornell University, Ithaca, NY 14853, USA
    FEBS Lett 585:865-9. 2011
    ..Our data provide a biological rationale for a two-step infection reaction during VSV entry, and suggest that BMP preferentially affects the ability of VSV G to mediate lipid mixing during membrane fusion...
  16. pmc VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling
    Phonphimon Wongthida
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Ther 19:150-8. 2011
    ..These paradoxically conflicting roles need to be carefully considered in future strategies designed to improve the efficacy of oncolytic virotherapy...
  17. pmc Functional analysis of late-budding domain activity associated with the PSAP motif within the vesicular stomatitis virus M protein
    Takashi Irie
    Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104 6049, USA
    J Virol 78:7823-7. 2004
    ..Finally, the insertion of the human immunodeficiency virus type 1 p6 L-domain and flanking sequences into the PSAP region of M protein rescued budding of a PPPY mutant of VSV to wild-type levels...
  18. pmc Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer
    Phonphimon Wongthida
    Departments of Molecular Medicine, Immunology, and Ophthalmology and Ocular Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Res 70:4539-49. 2010
    ..Lastly, the findings suggested new strategies to manipulate immune signals that may enhance viral replication, along with antitumor immune activation, and improve the efficacy of oncolytic virotherapies...
  19. ncbi Differential T cell costimulatory requirements in CD28-deficient mice
    A Shahinian
    Department of Medical Biophysics and Immunology, University of Toronto, Canada
    Science 261:609-12. 1993
    ..Thus, CD28 is not required for all T cell responses in vivo, suggesting that alternative costimulatory pathways may exist...
  20. pmc Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis
    S Balachandran
    Department of Microbiology and Immunology and Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida 33136, USA
    J Virol 75:3474-9. 2001
    ..Our data indicate that VSV shows significant promise as an effective oncolytic agent against a wide variety of malignant diseases that harbor a diversity of genetic defects...
  21. pmc Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus
    S A Kopecky
    Department of Microbiology and Immunology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1064, USA
    J Virol 75:12169-81. 2001
    ..These two viruses contain the same point mutation in their M proteins, suggesting that sequence differences in genes other than that for M protein affect their rates of induction of apoptosis...
  22. ncbi Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses
    Maryam Ahmed
    Department of Biochemistry, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Virology 330:34-49. 2004
    ....
  23. pmc Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates
    Nathan Jenks
    Toxicology and Pharmacology Laboratory, Mayo Clinic, Rochester, MN 55905, USA
    Hum Gene Ther 21:451-62. 2010
    ..On the basis of these studies, we will be proposing a cautious approach to dose escalation in a phase I clinical trial among patients with HCC...
  24. pmc CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response
    P Borrow
    Department of Neuropharmacology, Scripps Research Institute, La Jolla, California 92037, USA
    J Exp Med 183:2129-42. 1996
    ..Together, the results show that CD40-CD40L interactions are required for strong antiviral humoral immune responses, and reveal a novel role for CD40L in the establishment and/or maintenance of CD8+ CTL memory...
  25. pmc The distribution of fitness effects caused by single-nucleotide substitutions in an RNA virus
    Rafael Sanjuan
    Institut Cavanilles de Biodiversitat i Biologia Evolutiva, Universitat de Valencia, P O Box 22085, 46071 Valencia, Spain
    Proc Natl Acad Sci U S A 101:8396-401. 2004
    ..The proportion of beneficial mutations was unexpectedly high. Beneficial effects followed a gamma distribution, with expected fitness increases of 1% for random mutations and 5% for preobserved mutations...
  26. pmc Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity
    Masatsugu Obuchi
    Department of Microbiology and Immunology and Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida 33136, USA
    J Virol 77:8843-56. 2003
    ..Our data indicate that rVSV designed to exploit defects in mechanisms of host defense can provide the basis for new generations of effective, specific, and safer viral vectors for the treatment of malignant and other disease...
  27. ncbi Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy
    Brian D Lichty
    Ottawa Regional Cancer Centre Research Laboratories, Ottawa, Ontario, Canada K1H 1C4
    Hum Gene Ther 15:821-31. 2004
    ..This study demonstrates the potential utility of VSV in the treatment, both ex vivo and in vivo, of hematologic malignancies...
  28. pmc Targeting tumor vasculature with an oncolytic virus
    Caroline J Breitbach
    Centre for Cancer Therapeutics, Ottawa Health Research Institute, Ottawa, Ontario, Canada
    Mol Ther 19:886-94. 2011
    ..Blocking blood clot formation with thrombin inhibitors prevented tumor vascular collapse. Our results demonstrate that the therapeutic activity of an OV can go far beyond simple infection and lysis of malignant cells...
  29. ncbi Impaired immune and acute-phase responses in interleukin-6-deficient mice
    M Kopf
    Max Planck Institut fur Immunbiologie, Freiburg, Germany
    Nature 368:339-42. 1994
    ..We conclude that IL-6 production induced by injury or infection is an important in vivo SOS signal which coordinates activities of liver cells, macrophages and lymphocytes...
  30. ncbi Vesicular stomatitis virus glycoprotein containing the entire green fluorescent protein on its cytoplasmic domain is incorporated efficiently into virus particles
    K P Dalton
    Department of Pathology, Yale University School of Medicine, 310 Cedar Street, New Haven, Connecticut 06510-3218, USA
    Virology 279:414-21. 2001
    ....
  31. ncbi Recombinant vesicular stomatitis virus vectors as oncolytic agents in the treatment of high-grade gliomas in an organotypic brain tissue slice-glioma coculture model
    Christopher D Duntsch
    Department of Neurosurgery, The University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA
    J Neurosurg 100:1049-59. 2004
    ....
  32. ncbi Identification of a consensus mutation in M protein of vesicular stomatitis virus from persistently infected cells that affects inhibition of host-directed gene expression
    M Ahmed
    Department of Microbiology and Immunology, Bowman Gray School of Medicine of Wake Forest University, Medical Center Blvd, Winston Salem, North Carolina 27157, USA
    Virology 237:378-88. 1997
    ..These results support the idea that M gene mutations contribute to a reduced cytopathic effect in cells persistently infected with VSV...
  33. pmc Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes
    H Nishina
    Amgen Institute and Ontario Cancer Institute, Department of Medical Biophysics and Immunology, University of Toronto, M5G 2C1 Toronto, Ontario, Canada
    J Exp Med 186:941-53. 1997
    ..Our data provide the first genetic evidence that SEK1 is an important effector molecule that relays CD28 signaling to IL-2 production and T cell proliferation...
  34. ncbi Preferential targeting of vesicular stomatitis virus to breast cancer cells
    Ira Bergman
    Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, USA
    Virology 330:24-33. 2004
    ..Analysis of the protein composition of the rrVSV found low expression of the modified Sindbis gp on the virus...
  35. ncbi The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene
    Mercedes Porosnicu
    Department of Microbiology and Immunology and Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida 33136, USA
    Cancer Res 63:8366-76. 2003
    ....
  36. ncbi Potency of wild-type and temperature-sensitive vesicular stomatitis virus matrix protein in the inhibition of host-directed gene expression
    D S Lyles
    Department of Microbiology and Immunology, Bowman Gray School of Medicine of Wake Forest University, Winston Salem, North Carolina 27157, USA
    Virology 225:172-80. 1996
    ..Thus, inhibition of host transcription by ts M mutants of VSV is due to the potent activity of M protein, which is evident even at the low levels produced at the nonpermissive temperature...
  37. ncbi Crystal structure of the low-pH form of the vesicular stomatitis virus glycoprotein G
    Stephane Roche
    CNRS, Unité Mixte de Recherche UMR 2472, Institut Fédératif de Recherche IFR 115, Virologie Moléculaire et Structurale, 91198, Gif sur Yvette, France
    Science 313:187-91. 2006
    ..The structure provides a framework for understanding the reversibility of the G conformational change. Unexpectedly, G is homologous to gB of herpesviruses, which raises important questions on viral evolution...
  38. ncbi Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer
    Oliver Ebert
    Carl C Icahn Center for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Cancer Res 64:3265-70. 2004
    ..0078, log-rank test). The results suggest that fusogenic VSV can be developed into an effective and safe therapeutic agent for cancer treatment in patients, including those with multifocal HCC in the liver...
  39. pmc Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models
    Callinice D Capo-chichi
    Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL 33136, USA
    Gynecol Oncol 116:269-75. 2010
    ..Specifically, we examined the toxicity to hosts and specificity of targeting ovarian tumors using a Wv ovarian tumor model...
  40. ncbi Structure of the vesicular stomatitis virus nucleoprotein-RNA complex
    Todd J Green
    Department of Microbiology, School of Medicine, University of Alabama at Birmingham, 1025 18th Street South, Birmingham, AL 35294, USA
    Science 313:357-60. 2006
    ..This serves to protect the RNA in the absence of polynucleotide synthesis. For the RNA to be accessed, some conformational change in the N protein should be necessary...
  41. ncbi A FADD-dependent innate immune mechanism in mammalian cells
    Siddharth Balachandran
    Department of Microbiology and Immunology and Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida 33136, USA
    Nature 432:401-5. 2004
    ..These data therefore suggest the existence of a conserved pathogen recognition pathway in mammalian cells that is essential for the optimal induction of type I interferons and other genes important for host defence...
  42. ncbi Generation of high-titer pseudotyped retroviral vectors with very broad host range
    J K Yee
    Department of Pediatrics, City of Hope, Duarte, California 91010
    Methods Cell Biol 43:99-112. 1994
    ..Generation of stable packaging cell lines for the pseudotyped retroviral vectors is a major challenge for the future...
  43. ncbi The specific and essential role of MAVS in antiviral innate immune responses
    Qinmiao Sun
    Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Immunity 24:633-42. 2006
    ..These results provide the in vivo evidence that the cytosolic viral signaling pathway through MAVS is specifically required for innate immune responses against viral infection...
  44. pmc Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR
    Dionissios Baltzis
    Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Côte Ste Catherine St, Montreal, Quebec H3T 1E2, Canada
    J Virol 78:12747-61. 2004
    ..These findings further implicate PERK in virus infection, and provide evidence that the antiviral and antiapoptotic roles of PERK are mediated, at least in part, via the activation of PKR...
  45. ncbi VSV-tumor selective replication and protein translation
    Glen N Barber
    Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, FL 33136, USA
    Oncogene 24:7710-9. 2005
    ..Using VSV as a model, this review will discuss some of the recent developments in the fields of innate immunity and translational regulation that may help explain mechanisms of viral oncolysis...
  46. pmc Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host
    Isidoro Martinez
    Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Virol 77:8039-47. 2003
    ..These observations implicate the glycoprotein as a determinant of VSV virulence in a natural host and emphasize the differences in VSV pathogenesis between mice and swine...
  47. ncbi Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu
    Ira Bergman
    Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Int J Cancer 121:425-30. 2007
    ..These studies demonstrate that targeted rrVSV eliminated peritoneal implants of Her2/neu expressing tumor and elicited an anti-tumor T-cell immunologic response...
  48. ncbi Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes
    Andrea Hanika
    Institut fur Virologie, Stiftung Tierarztliche Hochschule Hannover, Bunteweg 17, D 30559 Hannover, Germany
    J Gen Virol 86:1455-65. 2005
    ..These findings suggest that pseudotyping of viral vectors with HEF might be useful for efficient apical gene transfer into polarized epithelial cells and for targeting cells that express 9-O-acetylated sialic acids...
  49. ncbi Unconventional mechanism of mRNA capping by the RNA-dependent RNA polymerase of vesicular stomatitis virus
    Tomoaki Ogino
    Department of Molecular Genetics, Section of Virology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Mol Cell 25:85-97. 2007
    ..Thus, the L proteins of VSV and, by extension, other NNS RNA viruses represent a new class of viral CEs, which have evolved independently from known eukaryotic CEs...
  50. pmc Epistasis and the adaptability of an RNA virus
    Rafael Sanjuan
    Institut Cavanilles de Biodiversitat i Biologia Evolutiva and Departament de Genètica, Universitat de Valencia, 46071 Valencia, Spain
    Genetics 170:1001-8. 2005
    ..Finally, for genotypes carrying two deleterious mutations, we found evidence of a negative correlation between the epistastic effect and the rate of compensatory evolution...
  51. pmc Gene expression contributing to recruitment of circulating cells in response to vesicular stomatitis virus infection of the CNS
    Derek D C Ireland
    Department of Biology, New York University, New York, New York 10003 6688, USA
    Viral Immunol 19:536-45. 2006
    ..Neutrophils are the first recruited cell type, appearing as early as 24 h after intranasal application of the virus. NK cells follow, but T cells are not detected until 6 days postinfection...
  52. pmc Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates
    J Erik Johnson
    Wyeth Vaccines Research, 401 N Middletown Road, Pearl River, NY 10965, USA
    Virology 360:36-49. 2007
    ..The implications of these findings for rVSV vaccine development are discussed...
  53. pmc Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line
    Yanhua Gao
    Department of Pediatrics, University of Pittsburgh School of Medicine, PA 15213, USA
    J Virol 80:8603-12. 2006
    ..The specificity for cells expressing the Her2/neu receptor was unchanged. These studies demonstrate that serial passage can be used to rapidly evolve a VSV genome encoding an improved chimeric glycoprotein...
  54. ncbi Inhibition of host RNA polymerase II-dependent transcription by vesicular stomatitis virus results from inactivation of TFIID
    H Yuan
    Department of Microbiology and Immunology, Wake Forest University School of Medicine, Winston Salem, North Carolina, 27157, USA
    Virology 251:383-92. 1998
    ..8 M KCl column fraction was not changed by VSV infection. These results indicated that VSV infection leads to an inhibition of host transcription by inactivation of TFIID rather than reduction in the level of TFIID...
  55. ncbi Transcriptional control of the RNA-dependent RNA polymerase of vesicular stomatitis virus
    John N Barr
    Department of Microbiology, BBRB 17, Room 366, University of Alabama School of Medicine, 845 19th Street S, Birmingham, AL 35294, USA
    Biochim Biophys Acta 1577:337-53. 2002
    ..Finally, the principles of transcriptional regulation have been utilized to develop a new paradigm for systematic attenuation of virulence to develop live attenuated viral vaccines...
  56. pmc Sequential coupling between COPII and COPI vesicle coats in endoplasmic reticulum to Golgi transport
    M Aridor
    Scripps Research Institute, Department of Cell Biology, La Jolla, California 92037, USA
    J Cell Biol 131:875-93. 1995
    ..We propose that sequential coupling between COPII and COPI coats is essential to coordinate and direct bi-directional vesicular traffic between the ER and pre-Golgi intermediates involved in transport of protein to the Golgi complex...
  57. pmc Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease
    Marilyn Fernandez
    Department of Microbiology and Immunology and Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida 33136, USA
    J Virol 76:895-904. 2002
    ..Our data demonstrate the validity of developing novel types of engineered VSV for recombinant protein production and as a gene therapy vector for the treatment of malignant and other disease...
  58. pmc Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction
    R N Harty
    Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, 19104, USA
    J Virol 75:10623-9. 2001
    ..These data suggest that the cellular ubiquitin-proteasome machinery is involved in the budding process of VSV and RV...
  59. pmc Peri-Golgi vesicles contain retrograde but not anterograde proteins consistent with the cisternal progression model of intra-Golgi transport
    J A Martinez-Menarguez
    Department of Cell Biology, School of Medicine, University of Murcia, 30071 Murcia, Spain
    J Cell Biol 155:1213-24. 2001
    ..These data suggest a role of peri-Golgi vesicles in recycling of Golgi residents, rather than an important role in anterograde transport...
  60. ncbi Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection
    S Balachandran
    Department of Microbiology and Immunology, University of Miami School of Medicine, Florida 33136, USA
    Immunity 13:129-41. 2000
    ..These results show that PKR is an essential component of innate immunity that acts early in host defense prior to the onset of IFN counteraction and the acquired immune response...
  61. ncbi Qualitative and quantitative requirements for CD4+ T cell-mediated antiviral protection
    K J Maloy
    Department of Pathology, Institute of Experimental Immunology, Zurich, Switzerland
    J Immunol 162:2867-74. 1999
    ..These results demonstrate that the antiviral properties of CD4+ T cells are governed by the differentiation status of the CD4+ T cell and by the type of effector response required for virus elimination...
  62. ncbi Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus
    M A DeBenedette
    Department of Immunology, University of Toronto, Ontario, Canada
    J Immunol 163:4833-41. 1999
    ..These results further substantiate the idea that different immune responses vary in their dependence on costimulation and suggest a role for 4-1BBL in augmenting suboptimal CTL responses in vivo...
  63. pmc Differential thymic selection outcomes stimulated by focal structural alteration in peptide/major histocompatibility complex ligands
    Y Ghendler
    Laboratory of Immunobiology, Dana Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 95:10061-6. 1998
    ..Based on these finding and the recent structural elucidation of the N15-VSV8/Kb complex, moreover, it appears that the germ-line Valpha repertoire contributes in a significant way to positive selection...
  64. pmc Visualization of intracellular transport of vesicular stomatitis virus nucleocapsids in living cells
    Subash C Das
    Department of Veterinary and Biomedical Sciences and Nebraska Center for Virology, University of Nebraska Lincoln, E126 Beadle Center, 1901 Vine Street, Lincoln, NE 68588, USA
    J Virol 80:6368-77. 2006
    ..These findings are compatible with a model in which the progeny viral nucleocapsids are transported toward the cell periphery by MT and the transport may be facilitated by mitochondria...
  65. pmc Exponential fitness gains of RNA virus populations are limited by bottleneck effects
    I S Novella
    Department of Biology and Center for Molecular Genetics, University of California, San Diego, La Jolla, California 92093 0116, USA
    J Virol 73:1668-71. 1999
    ..This effect appears likely to be due to bottleneck effects on very high fitness populations...
  66. ncbi IL-12 is not required for induction of type 1 cytokine responses in viral infections
    A Oxenius
    Institute of Experimental Immunology, Department of Pathology, University of Zurich, Switzerland
    J Immunol 162:965-73. 1999
    ....
  67. pmc Recycling of golgi-resident glycosyltransferases through the ER reveals a novel pathway and provides an explanation for nocodazole-induced Golgi scattering
    B Storrie
    Department of Biochemistry, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061 0308, USA
    J Cell Biol 143:1505-21. 1998
    ..In conclusion, we have shown that Golgi-resident glycosylation enzymes recycle through the ER and that this novel pathway is the likely explanation for the nocodazole-induced Golgi scattering observed in interphase cells...
  68. ncbi Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA
    G Uze
    Laboratoire d Oncologie virale, CNRS UPR 274, Villejuif, France
    Cell 60:225-34. 1990
    ..Mouse cells expressing the cDNA become sensitive to the antiviral activity of and express binding sites for human interferon alpha, demonstrating that the cloned cDNA encodes a functional human interferon alpha receptor...
  69. ncbi Contribution of Taq polymerase-induced errors to the estimation of RNA virus diversity
    M A Bracho
    Departament de Genetica, Universitat de Valencia, Spain
    J Gen Virol 79:2921-8. 1998
    ....
  70. ncbi Structures of vesicular stomatitis virus glycoprotein: membrane fusion revisited
    S Roche
    CNRS, UMR2472, INRA, UMR1157, IFR 115, Virologie Moléculaire et Structurale, Gif sur Yvette, France
    Cell Mol Life Sci 65:1716-28. 2008
    ..Besides the similarities with other viral fusion machineries, the fusion properties and structures of G also reveal some striking particularities that invite us to reconsider a few dogmas concerning fusion proteins...
  71. pmc A single amino acid change in the L-polymerase protein of vesicular stomatitis virus completely abolishes viral mRNA cap methylation
    Valery Z Grdzelishvili
    University of Florida College of Medicine, Department of Molecular Genetics and Microbiology, 1600 S W Archer Road, P O Box 100266, Gainesville, FL 32610 0266, USA
    J Virol 79:7327-37. 2005
    ..Sequence analysis suggests that an aspartic acid at amino acid 1671 is a critical residue within a putative conserved S-adenosyl-l-methionine-binding domain of the L protein...
  72. pmc Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice
    U Steinhoff
    Department of Pathology, University of Zurich, Switzerland
    J Virol 69:2153-8. 1995
    ....
  73. pmc Amino acid residues within conserved domain VI of the vesicular stomatitis virus large polymerase protein essential for mRNA cap methyltransferase activity
    Jianrong Li
    HMS Microbiology, 200 Longwood Avenue, Boston, MA 02115, USA
    J Virol 79:13373-84. 2005
    ..A model of mRNA processing consistent with these data is presented...
  74. pmc The organization of endoplasmic reticulum export complexes
    S I Bannykh
    Scripps Research Institute, Department of Cell Biology, La Jolla, California 92130, USA
    J Cell Biol 135:19-35. 1996
    ....
  75. pmc Structure of the vesicular stomatitis virus nucleocapsid in complex with the nucleocapsid-binding domain of the small polymerase cofactor, P
    Todd J Green
    Department of Microbiology, University of Alabama School of Medicine, Birmingham, AL 35294, USA
    Proc Natl Acad Sci U S A 106:11713-8. 2009
    ..Localization of phosphorylation sites within P and their proximity to the RNA cavity give insight into how the L protein might be oriented to access the RNA template...
  76. ncbi Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes
    H F Gallardo
    Department of Human Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 90:952-7. 1997
    ..Nonetheless, the physical stability of VSV-G-coated particles enables the concentration of viral stocks to 10(9) infectious particles per milliliter or more...
  77. ncbi Study on risk factors for transplacental viral infections; effect of bacterial factors and double viral infections on virus replication in placenta and amniotic membranes
    B Jatczak
    Laboratory of Virology, Institute Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, , Poland
    Placenta 22:360-71. 2001
    ..Contribution of endogenous TNFalpha in both reactions (stimulation and inhibition) was confirmed using antibodies against the TNF...
  78. ncbi Three distinct steps in transport of vesicular stomatitis virus glycoprotein from the ER to the cell surface in vivo with differential sensitivities to GTP gamma S
    R Pepperkok
    Department of Cell Biology, Sciences III, University of Geneva, CH 1211 Geneva 4, Switzerland
    J Cell Sci 111:1877-88. 1998
    ..COPI plays a role in subsequent transport to the Golgi complex, and a so far unidentified GTP gamma S sensitive coat appears to be involved in transport from the TGN to the cell surface...
  79. pmc A unique strategy for mRNA cap methylation used by vesicular stomatitis virus
    Jianrong Li
    Department of Microbiology and Molecular Genetics, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 103:8493-8. 2006
    ..These findings suggest that VSV evolved an unusual strategy of mRNA cap methylation that may be shared by other nsNS RNA viruses...
  80. pmc Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus
    L A Ball
    Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    J Virol 73:4705-12. 1999
    ..As a consequence, gene rearrangement should be irreversible and provide an approach for constructing viruses with novel phenotypes...
  81. ncbi Resistance to viral infection of super p53 mice
    Cesar Munoz-Fontela
    Departamento de Microbiologia II, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramon y Cajal sn, Madrid 28040, Spain
    Oncogene 24:3059-62. 2005
    ..These findings unequivocally demonstrate an antiviral activity of p53, a process that may contribute to inhibit the spread of the virus in vivo...
  82. pmc Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge
    J S Kahn
    Department of Pediatrics, Division of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    J Virol 75:11079-87. 2001
    ..The attenuated, nonpropagating VSVDeltaG-RSV F is a particularly attractive candidate for a live attenuated recombinant RSV vaccine...
  83. pmc Transcription and replication initiate at separate sites on the vesicular stomatitis virus genome
    Sean P J Whelan
    Department of Microbiology, University of Alabama School of Medicine, 845 19th Street S, Birmingham, AL 35294, USA
    Proc Natl Acad Sci U S A 99:9178-83. 2002
    ..By applying UV transcriptional mapping to engineered variants of vesicular stomatitis virus, we discovered that, in infected cells, transcription and replication are controlled by initiation at different positions on the viral genome...
  84. pmc Preferential translation of vesicular stomatitis virus mRNAs is conferred by transcription from the viral genome
    Zackary W Whitlow
    Department of Biochemistry, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Virol 80:11733-42. 2006
    ..This indicated that VSV mRNAs do contain cis-acting structural elements (that are not sequence based), which enhance translation efficiency of viral mRNAs...
  85. ncbi OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection
    M Kopf
    Basel Institute for Immunology, Basel, Switzerland
    Immunity 11:699-708. 1999
    ..Moreover, the number of CD4+ T cells infiltrating the lungs of influenza virus-infected OX40-/- mice was reduced. These results define a unique role of OX40 in the generation of optimal CD4+ T cell responses in vivo...
  86. ncbi Age related natural antiviral non-specific immunity of human leukocytes
    Katarzyna Rybka
    Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland
    Med Sci Monit 9:BR413-7. 2003
    ..The purpose of our study was to examine the dependence of innate antiviral immunity on age and sex in human leukocytes...
  87. ncbi Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats
    Oliver Ebert
    Carl C Icahn Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    Cancer Res 63:3605-11. 2003
    ..Our results show that VSV is an effective oncolytic agent against HCC in immune-competent hosts and warrants further development for future therapy in patients with HCC...
  88. ncbi An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants
    N F Rose
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
    Cell 106:539-49. 2001
    ..Protection from AIDS was highly significant (p = 0.001). VSV vectors are promising candidates for human AIDS vaccine trials because they propagate to high titers and can be delivered without injection...
  89. ncbi Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G
    Stephane Roche
    CNRS, Unité Mixte de Recherche UMR 2472, Institut National de la Recherche Agronomique INRA, UMR 1157, Institut Fédératif de Recherche 115, Laboratoire de Virologie Moleculaire et Structurale, 91198, Gif sur Yvette, France
    Science 315:843-8. 2007
    ..A large number of G glycoproteins, perhaps organized as in the crystals, act cooperatively to induce membrane merging...
  90. pmc An antiviral role for the RNA interference machinery in Caenorhabditis elegans
    Daniel H Schott
    Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138, USA
    Proc Natl Acad Sci U S A 102:18420-4. 2005
    ..Our observation that multiple genes required for RNAi are also required for resistance to vesicular stomatitis virus suggests that the RNAi machinery functions in resistance to viruses in nature...
  91. ncbi Constitutive expression of (2'-5') oligo A synthetase confers resistance to picornavirus infection
    J Chebath
    Department of Virology, Weizmann Institute of Science, Rehovot, Israel
    Nature 330:587-8. 1987
    ..Elevated enzyme correlates directly with resistance to infection by a picornavirus such as Mengo, but does not make the cells resistant to vesicular stomatitis virus (VSV)...
  92. ncbi Double-positive T cell receptor(high) thymocytes are resistant to peptide/major histocompatibility complex ligand-induced negative selection
    Y Ghendler
    Laboratory of Immunobiology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Eur J Immunol 27:2279-89. 1997
    ..Hence, negative selection processes involving MHC-bound peptide ligands are operative only prior to the late DP thymocyte stage in this MHC class I-restricted TCR transgene system...
  93. ncbi SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector
    Sagar U Kapadia
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
    Virology 376:165-72. 2008
    ..Our results, along with earlier studies showing potent induction of T-cell responses by single-cycle vectors, indicate that these vectors are excellent alternatives to live-attenuated VSV...
  94. pmc Overproduction of double-stranded RNA in vesicular stomatitis virus-infected cells activates a constitutive cell-type-specific antiviral response
    Derek Ostertag
    Department of Biology, Center for Microbial Sciences, San Diego State University, 5500 Campanile Drive, San Diego, CA 92182, USA
    J Virol 81:503-13. 2007
    ..We conclude that, for some cell types, overproduction of dsRNA during VSV infection triggers an immediate and constitutive host cell antiviral effector response independent of interferon induction or signaling...
  95. ncbi RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates
    Andreas Pichlmair
    Immunobiology Laboratory, Cancer Research UK, London Research Institute, London WC2A 3PX, UK
    Science 314:997-1001. 2006
    ....
  96. ncbi Factors that influence VSV-G pseudotyping and transduction efficiency of lentiviral vectors-in vitro and in vivo implications
    Daniel C Farley
    Oxford BioMedica Ltd, The Medawar Centre, Robert Robinson Avenue, Oxford Science Park, Oxford OX4 4GA, UK
    J Gene Med 9:345-56. 2007
    ..The implications of these data with regard to VSV-G-pseudotyped vector production, titration, and use in host-cell restriction studies, are discussed...
  97. pmc L-domain flanking sequences are important for host interactions and efficient budding of vesicular stomatitis virus recombinants
    Takashi Irie
    Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, 19104, USA
    J Virol 79:12617-22. 2005
    ..We demonstrate that the composition of amino acids surrounding the L-domain core motifs are critical for efficient L-domain activity and for interactions with host proteins in the context of a VSV infection...
  98. ncbi Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein
    Shuetsu Fukushi
    Special Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases, Gakuen 4 7 1, Musashimurayama, Tokyo 208 0011, Japan
    J Gen Virol 86:2269-74. 2005
    ..VSV-SARS-St19 will be useful for analysing the function of SARS-CoV-S protein and for developing rapid methods of detecting neutralizing antibodies specific for SARS-CoV infection...
  99. ncbi Tropism of lentiviral vectors in skin tissue
    Nikolai Kunicher
    Department of Virology, Hebrew University Hadassah Medical School, Jerusalem 91120, Israel
    Hum Gene Ther 19:255-66. 2008
    ..In conclusion, we show that lentiviral tropism in a solid tissue is dependent on several factors, extra- and intracellular, distinct of the cellular receptors...
  100. ncbi ISG15 enhances the innate antiviral response by inhibition of IRF-3 degradation
    G Lu
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Cell Mol Biol (Noisy-le-grand) 52:29-41. 2006
    ....
  101. ncbi Arrested spread of vesicular stomatitis virus infections in vitro depends on interferon-mediated antiviral activity
    Vy Lam
    Department of Chemical and Biological Engineering, 1415 Engineering Drive, University of Wisconsin, Madison, Wisconsin 53706 1607, USA
    Biotechnol Bioeng 90:793-804. 2005
    ..This study demonstrates a mechanism for quantifying how innate cellular responses can mitigate infection spread in vitro...

Research Grants62

  1. Mechanisms of VSV-mediated Oncolysis
    Glen N Barber; Fiscal Year: 2010
    ..Understanding how these pathways function has significant impact on understanding pathogenesis and for developing novel therapeutics and vaccines to combat disease. ..
  2. Determinants of RNA virus evolution
    ISABEL NOVELLA; Fiscal Year: 2009
    ....
  3. SURVIVAL AND EXTINCTION IN RNA VIRUS POPULATIONS
    ISABEL NOVELLA; Fiscal Year: 2003
    ..Specifically, the proposal will address the effect of antibody response and of replication in insect vectors, on virus survival and adaptation. ..
  4. Targeted Recombinant VSV Virus to Treat Breast Cancer
    Ira Bergman; Fiscal Year: 2008
    ..The proposal focuses on breast cancer but could be equally applied to many other cancers for which suitable cell surface targets exist. [unreadable] [unreadable]..
  5. Budding of Negative-sense RNA Viruses
    RONALD HARTY; Fiscal Year: 2006
    ....
  6. VSV-based Therapeutic Papilloma Vaccine
    Janet Brandsma; Fiscal Year: 2007
    ..The data provided by this investigation are likely to aid in the development a highly effective HPV vaccine to protect women against cervical cancer. ..
  7. Papillomavirus E2 as a cervical/anal cancer drug target
    Janet Brandsma; Fiscal Year: 2005
    ..Vectors containing a conditional wild-type CRPV E2 transgene will be used to determine the effects of E2 overexpression. ..
  8. Immunogenicity of Hepatitis C Virus (HCV) like particles
    Glen Barber; Fiscal Year: 2007
    ..abstract_text> ..
  9. Ebola Virus VP40-Host Interactions In VIvo
    RONALD HARTY; Fiscal Year: 2005
    ..These studies will be fundamental for our understanding of Ebola virus budding and necessary for the successful development of future therapeutic approaches. ..
  10. Packaging of Ebola Virus RNA into Budding VLPs
    RONALD HARTY; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  11. VIRUS PHOTOINACTIVATION--DIMETHYLMETHYLENE BLUE IN RBC
    Stephen Wagner; Fiscal Year: 2004
    ..abstract_text> ..
  12. Role of PKR in Growth Regulation
    Glen Barber; Fiscal Year: 2008
    ..We propose that these aims will lend insight into mechanisms of cell signaling, tumorigenesis and interferon-mediated actions in the cell. ..
  13. A FADD-Associated Helicase Essential for Host Defense
    Glen Barber; Fiscal Year: 2008
    ..We anticipate that these studies will improve our knowledge of pathogenesis and provide new concepts for the rational design of novel therapeutic and vaccine strategies. [unreadable] [unreadable] [unreadable]..
  14. Targeted Therapy for Burkitt Lymphoma in Resource Poor Settings
    Glen N Barber; Fiscal Year: 2010
    ..Our long term goal is to develop a targeted, efficacious, antiviral-based therapy for EBV (HIV) associated lymphoma that is applicable in developing nations. ..
  15. Innate Intracellular Mechanisms
    Glen N Barber; Fiscal Year: 2010
    ..The importance of STING in innate signaling will be determined. Understanding how these pathways function has significant impact on understanding pathogenesis and for developing novel therapeutics and vaccines to combat disease. ..
  16. FUNCTION ANALYSIS OF THE DSRNA REGULATED NUCLEAR FACTORS
    Glen Barber; Fiscal Year: 2004
    ..abstract_text> ..
  17. Analysis of the Ebola Virus VP24 Channel Protein
    RONALD HARTY; Fiscal Year: 2003
    ..Overall this application will address key mechanisms of Ebola virus pathogenesis that may lead to the development of novel paradigms with direct impact on the development of therapeutic approaches. ..
  18. Virus-Receptor Interaction and CYP3A Expression
    Maria Croyle; Fiscal Year: 2005
    ....
  19. Suppression of Hepatic Gluconeogenesis in IDDM
    Savio Woo; Fiscal Year: 2004
    ..The research proposed in this project can potentially lead to development of an effective and safe adjuvant treatment to complement insulin therapy and significantly improve glycemic control in patients with IDDM. ..
  20. T CELL ANTIGEN RECOGNITION
    Ellis Reinherz; Fiscal Year: 2008
    ..The completion of these experiments will be instrumental in defining specific modes of movement and illuminating the structural mechanism by which TCR signaling is initiated. ..
  21. T CELL ANTIGEN RECOGNITION
    Ellis L Reinherz; Fiscal Year: 2010
    ..abstract_text> ..
  22. Control of elF4F complex by Vesicular Stomatitis Virus
    John Connor; Fiscal Year: 2007
    ....
  23. Hepatitis C Virus Induced IL-8 & Inhibition of Interferon
    STEPHEN POLYAK; Fiscal Year: 2007
    ..Moreover, IL-8 or its receptors may prove to be suitable targets for therapeutic intervention in chronic hepatitis C. ..
  24. Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
    Savio L Woo; Fiscal Year: 2010
    ....
  25. Mechanisms of RNA virus-host interaction
    Sailen Barik; Fiscal Year: 2009
    ..Together, these results should lead to a better understanding of the replication of RSV in particular and of RNA viruses in general, and pave the way for a more reliable management of the viral diseases. ..
  26. Mutagenic analysis of LPS responses
    Bruce Beutler; Fiscal Year: 2006
    ..In the case of mutations that abolish LPS tolerance, we will attempt to determine the net impact on host resistance to infection. ..
  27. Genes that Mediate Tolerance to the Placental Allograft
    Bruce Beutler; Fiscal Year: 2006
    ..Fourth, circumvention of the toleragenic mechanism might be used to prevent normal gestation, leading to termination of pregnancy within a few days following implantation of the blastocyst. ..
  28. Protein synthesis control by vesicular stomatits virus
    John Connor; Fiscal Year: 2004
    ..These project is designed to develop an independent research program focused on discovering more about mechanisms of both viral and host protein translation with an interest in applying the lessons learned to cancer therapy. ..
  29. CELLULAR FACTORS INVOLVED IN NUCLEAR EXPORT OF VIRAL RNA
    Flossie Wong Staal; Fiscal Year: 2001
    ....
  30. REVERSIBLE PROTEIN PHOSPHORYLATION IN APICOMPLEXANS
    Sailen Barik; Fiscal Year: 2004
    ..These results should form the cornerstone in the detailed elucidation of the regulatory pathways and possible drug-target interactions in Plasmodium in particular, and Apicomplexans in general. ..
  31. GABA: EXCITATORY TRANSMITTER IN DEVELOPING HYPOTHALAMUS
    Anthony van den Pol; Fiscal Year: 2008
    ..GABA's excitatory actions during development are widespread throughout the brain. Thus, what we learn from our experiments on hypothalamic neurons should have general applicability to other CNS neurons. ..
  32. POSITIVE SELECTION OF THYMOCYTES
    Ellis Reinherz; Fiscal Year: 2004
    ..Fourth, the potential role for germline Valpha genes in positive selection will be assessed, with emphasis on CDR1 as suggested by x-ray analysis of N15- VSV8/K/b co-crystals. ..
  33. Hepatitis C Virus Proteins and Ethanol
    STEPHEN POLYAK; Fiscal Year: 2004
    ..abstract_text> ..
  34. REPLICATION AND ENCAPSIDATION OF NODAVIRUS RNAS
    L Ball; Fiscal Year: 2004
    ....
  35. Cytokine activation of neurons
    CAROL REISS; Fiscal Year: 2009
    ..They elucidate previously unsuspected interactions between the immune system and the central nervous system. ..
  36. Genetic Reconstitution for Phenylketonuria
    Savio Woo; Fiscal Year: 2006
    ..abstract_text> ..
  37. TRANSMEMBRANE DOMAINS IN MEMBRANE FUSION
    John Lenard; Fiscal Year: 2003
    ..These experiments are expected to lead to a unified and comprehensive understanding of the role of the TMD in both viral and cellular fusion reactions. ..
  38. Cytomegalovirus in the Brain
    Anthony N van den Pol; Fiscal Year: 2010
    ..These experiments will help us understand the mechanisms associated with CMV-induced neurological dysfunction, and how to combat the virus within the brain with minimal complications. ..
  39. Assembly of the negative stranded RNA virus core
    Ming Luo; Fiscal Year: 2010
    ..M was copurified with the P-N-RNA complex. Crystallization and cryoEM studies of this complex are in progress. The result will show how M may interact with the N-RNA complex, and perhaps with P as well. ..
  40. NPY DEPRESSION OF HIPPOCAMPAL EPILEPSY
    Anthony van den Pol; Fiscal Year: 2002
    ..NPY is potentially of great interest because its primary action in the normal hippocampus appears to be one of depressing hyperexcited neurons, without a substantial effect on normal neurotransmission. ..
  41. RIBOZYME GENE THERAPY FOR CD4 AND CD34 CELLS
    Flossie Wong Staal; Fiscal Year: 2001
    ..Thus, our goals are to prepare and validate the first generation of polyRz vector as well as to design the next generation of polyRz vector which incorporate Rz's against potential resistant mutations and other co-receptors. ..
  42. Hypocretin Neurons
    Anthony N van den Pol; Fiscal Year: 2010
    ..Understanding the role of the endogenous opioid in hypocretin cells should also facilitate the understanding and treatment of narcolepsy. ..
  43. VSV INFECTION OF THE CENTRAL NERVOUS SYSTEM
    CAROL REISS; Fiscal Year: 2005
    ..This work has both basic and clinical applications, as viral encephalitis and pathological changes in the BBB are important medical problems. ..
  44. Epithelial gene expression in HIV-associated nephropathy
    Michael Ross; Fiscal Year: 2006
    ..It is also possible that genes implicated in the pathogenesis of HIVAN maybe important factors contributing to the marked predisposition of African-Americans to nearly all causes of renal failure. ..
  45. TLR4 as an LPS sendor and susceptibility locus
    Bruce Beutler; Fiscal Year: 2007
    ..The new mutations that are found--and those that have already been found in preliminary efforts--will be isolated by positional cloning. ..
  46. FAT10 a candidate gene for epithelial apoptosis in HIV-associated nephropathy
    Michael Ross; Fiscal Year: 2007
    ..These studies will advance our understanding of HIVAN pathogenesis and may yield a novel therapeutic target for the treatment of HIVAN and other renal diseases. [unreadable] [unreadable]..
  47. Vector Core Production Facility at Mount Sinai
    Savio Woo; Fiscal Year: 2006
    ..abstract_text> ..
  48. Sterols and Aging in C. Elegans
    John Lenard; Fiscal Year: 2005
    ..We expect to reveal novel mechanisms of sterol action in both development and aging, and we postulate that these will have parallels in higher organisms. ..
  49. Viral Stress-inducible Gene Expression
    Ganes Sen; Fiscal Year: 2005
    ..These studies will illuminate the modes of cross-talk between the TLR and the Jak-STAT signaling pathways for appropriate gene induction in virus-infected cells. ..
  50. The Role of a Novel Coronavirus In Kawasaki Disease
    Jeffrey Kahn; Fiscal Year: 2007
    ..We have identified a novel human virus, designated the New Haven coronavirus that is associated with KD. The goals of this study is to investigate the role of this novel virus in KD. [unreadable] [unreadable]..
  51. Anaerobic Bacteria as Therapeutic Agents for Metastatic Cancer
    Savio Woo; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  52. BIOMARKERS FOR DIAGNOSIS & MANAGEMENT OF PROSTATE CANCER
    Kailash Chadha; Fiscal Year: 2007
    ..New biomarkers that will have clinical impact and will facilitate to maximize the use of current therapies and to evaluate the future novel, potentially more effective therapies are needed. [unreadable] [unreadable]..
  53. GENES ENCODING T CELL RECEPTORS
    Ellis Reinherz; Fiscal Year: 2006
    ..Third, the molecular mechanism by which the CD2 cytoplasmic tail interacting proteins CD2BP1, CD2BP3 and CD2BP4 affect cell motility, polarity and lipid biogenesis will be investigated. ..
  54. INHIBITION OF NUCLEO-CYTOPLASMIC TRANSPORT BY RHINOVIRUS
    KURT GUSTIN; Fiscal Year: 2005
    ..Proteins will be identified by mass spectroscopy and compared with those isolated from uninfected cells. Immunoelectron microscopy will be used to determine structural changes that are a consequence of viral infection. ..
  55. HEPATIC INSULIN GENE EXPRESSION IN IDDM
    Savio Woo; Fiscal Year: 2001
    ..Successful conduct of the proposed research will lead to the development of a novel modality for adjuvant treatment of IDDM in humans. ..
  56. Interactions between ocular tissue and RSV
    Sailen Barik; Fiscal Year: 2004
    ..be proven, it would establish an animal model for RSV-eye interaction, and open new directions in ocular immunopathology, RNA virus-activated signaling pathways in the eye, and antiviral drug regimen targeting the eye ..
  57. Role of DAP12 in type 1 anti-mycobacterial immunity
    Zhou Xing; Fiscal Year: 2005
    ..We strongly believe that our studies will provide new insights into the mechanisms of type 1 anti-microbial immunity and novel targets for immune modulation. ..
  58. Forward Genetic Analysis of the Innate Immune Contribution to MCMV Resistance
    Bruce Beutler; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  59. Gene delivery methods for global therapy in the CNS
    Miguel Esteves; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  60. Anaerobic Bacteria as Oncopathic Agents for Pancreatic Cancer
    Savio Woo; Fiscal Year: 2009
    ..Anaerobic bacteria can target the hypoxic cores in tumors that will be complementary to chemotherapy, such that the outcome of combination treatment will be superior to chemotherapy alone. ..